Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 5/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.33 |
| ▸ | SKP1 | P63208 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16608907 | 1.00 | RET (0.41) | RETOPRK1MAPTTDP1SUV39H2 | |
| SCHEMBL16608911 | 1.00 | RET (0.41) | RETOPRK1MAPTTDP1SUV39H2 | |
| SCHEMBL16608964 | 1.00 | RET (0.41) | RETOPRK1MAPTTDP1SUV39H2 | |
| SCHEMBL18167420 | 0.88 | ABCC2 (0.40) | OPRK1MAPTTDP1ABCC2 | |
| SCHEMBL17965893 | 0.88 | ABCC2 (0.40) | OPRK1MAPTTDP1ABCC2 | |
| SCHEMBL18167424 | 0.88 | ABCC2 (0.40) | OPRK1MAPTTDP1ABCC2 | |
| SCHEMBL18167421 | 0.88 | ABCC2 (0.40) | OPRK1MAPTTDP1ABCC2 | |
| SCHEMBL18167422 | 0.88 | ABCC2 (0.40) | OPRK1MAPTTDP1ABCC2 | |
| SCHEMBL16608976 | 0.84 | CKS1B (0.45) | OPRK1MAPTTDP1SUV39H2CKS1B | |
| SCHEMBL16695012 | 0.78 | CKS1B (0.47) | MAPTTDP1SUV39H2CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643951-B2 | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-09 | — | — | US | disclosed |
| US-9643951-B2 | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20160311794-A1 | COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160311794-A1 | COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-10-27 | — | — | US | disclosed |
| WO-2015046482-A1 | COMPOUND HAVING AGONISTIC ACTIVITY TO SOMATOSTATIN RECEPTOR AND MEDICINAL USE THEREOF | 小野薬品工業株式会社 | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311794-A1 | COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF | SSTR1, SSTR2, SSTR3 | RET 127/4885OPRK1 1050/4885MAPT 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.